StartUPDATES: New Developments from Healthcare Startups
Check out news from Alpha Sophia, Handl Health, Alaffia Health, and Summer Health
Check out news from Alpha Sophia, Handl Health, Alaffia Health, and Summer Health
Two Japanese pharmaceutical companies and a bank are teaming up to form a joint venture to advance therapeutic discoveries from academia. The focus will be innovation from universities in Japan.
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
In addition to panel discussions around some of the hottest topics in healthcare transformation, there is also a startup pitch contest, a presentation on government funding for startups and networking opportunities.
These health tech companies focused on the consumer and self-insured employer market will take part in the MedCity INVEST Pitch Perfect contest May 21-22 in Chicago. Register today!
Seaport Therapeutics’ drug candidates are delivered through the lymphatic system, an approach that could overcome some limitations of neuropsychiatric medicines, including products from Sage Therapeutics. The startup stems from the research of PureTech Health.
Diagonal Therapeutics develops agonist antibodies to treat rare cardiovascular conditions. Using artificial intelligence, the startup’s technology sorts through billions of antibody/receptor combinations to identify the ones that reactivate signaling pathways lost to disease.
Mirador Therapeutics applies machine learning to human data to discover new immunology and inflammation drugs. The startup’s management includes several from the executive team of Prometheus Biosciences, an immunology biotech bought by Merck last year.
Clasp Therapeutics’ novel T cell engagers could offer advantages over others in this class of cancer immunotherapies. The startup is based on the research of Johns Hopkins University scientist Bert Vogelstein.
At the MedCity INVEST conference, scheduled for May 21-22 at the Ritz Carlton in Chicago, health benefits in the context of value-based care will be one of several topics of discussion at the boutique healthcare investment event. Register today!
Tubulis’s next-generation ADC cancer drugs are designed to overcome limitations of currently available therapies in this drug class. The new financing will support clinical trial plans, but first, preclinical proof-of-concept data will be presented during the American Association for Cancer Research annual meeting.
We will highlight Build My Health's revenue practice management tools, which could help physician practices add up to $250,000 to their practices.
Check out news from Band Connect, Fijoya, Team8, and BrainCheck.
The premier boutique healthcare investment conference is scheduled for May 21-22 at the Ritz Carlton hotel in Chicago
Check out news from Alpha Sophia, Abridge, Baseimmune, Carewell, and Redi Health.
Orbis Medicines is developing macrocyclic peptides that address a wider range of targets and can be taken as oral pills. Novo Holdings and Forbion are backing the startup, which is based on research from the scientific co-founder of peptide drug developer Bicycle Therapeutics.
Regenerative medicine startup Pelage Pharmaceuticals has clinical data showing its small molecule activated hair follicle stem cells. GV led a Series A round that funded the UCLA spinout’s Phase 1 clinical trial and will also support Phase 2 testing this year.